Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rezolute, Inc. (Nasdaq: RZLT) SEC filings page provides access to the company’s regulatory disclosures as a publicly traded, late-stage rare disease company focused on hypoglycemia caused by hyperinsulinism. Through these documents, investors can review how Rezolute reports on its clinical programs, financial condition, governance and shareholder matters.
Current reports on Form 8-K include items such as clinical and business updates, financial results, and corporate actions. For example, recent 8-K filings reference press releases on quarterly and annual financial results, alignment with the U.S. Food and Drug Administration on the design of the Phase 3 upLIFT study in tumor hyperinsulinism, and updates on the ersodetug development program. Other 8-Ks describe material agreements, executive appointments, amendments to employment arrangements, and the termination of an at-the-market equity program.
Proxy materials, such as the definitive proxy statement on Schedule DEF 14A, outline proposals presented at Rezolute’s annual meeting of stockholders. These include the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, amendments to the company’s equity incentive plan, and potential adjournment proposals. Related 8-K filings report the final voting results for these matters.
Investors can also use this page to locate filings that incorporate press releases on financial results, which provide additional context on research and development spending, general and administrative expenses, and net loss figures, as described by the company. While this page focuses on accessing the underlying SEC documents, AI-powered tools on the platform can help summarize key points from lengthy filings, highlight important sections, and make it easier to understand Rezolute’s disclosures on clinical progress, compensation policies and capital structure.
Together, these SEC filings form an official record of Rezolute’s activities as a Nasdaq-listed issuer developing its lead monoclonal antibody therapy, ersodetug, for congenital and tumor hyperinsulinism.
Rezolute, Inc. (RZLT) filed its quarterly report, highlighting continued late-stage development of ersodetug and typical clinical-stage losses. The company reported a net loss of
Liquidity remains strong with cash and cash equivalents of
Key pipeline updates include the Phase 3 sunRIZE study in congenital hyperinsulinism with topline data anticipated in December 2025, and FDA-agreed modifications to the Phase 3 upLIFT trial in tumor hyperinsulinism to a single-arm, open-label design in as few as 16 participants. Capital actions included an April 2025 underwritten offering with approximately
Rezolute, Inc. (RZLT) furnished an 8‑K announcing it issued a press release with financial results for the first quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The information, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Exchange Act. Rezolute’s common stock trades on the Nasdaq Capital Market under the symbol RZLT.
Rezolute, Inc. reported two corporate actions. The company amended employment agreements for its CEO Nevan C. Elam, CMO Brian Roberts, CFO Daron Evans, and CCO Sunil Karnawat to provide a full gross-up payment for any excise tax and related taxes arising from “excess parachute payments” in a change of control under Section 280G. The company will determine the gross-up amount in its sole discretion, and the amendments will be filed with the next Form 10-Q.
Rezolute also delivered written notice to terminate its Open Market Sale Agreement with Jefferies LLC, effective October 24, 2025. The agreement supported an at-the-market program established under a November 2023 S-3 shelf. The company states it did not undertake any sales under the at-the-market program.
Rezolute, Inc. is asking shareholders to vote at the Annual Meeting on a slate of routine corporate matters including election of seven director nominees, ratification of Grant Thornton LLP as independent auditor, a non-binding advisory vote on executive compensation, and an amendment to the 2021 Equity Incentive Compensation Plan to increase available shares from 14,450,000 to 21,950,000. The proxy materials will be delivered primarily via internet starting on or about
Rezolute, Inc. Schedule 13G summary: This filing reports that several affiliated entities and individuals associated with Invus and Avicenna disclosed beneficial ownership of Rezolute common stock. Invus Public Equities directly holds 4,171,401 shares (about 4.6% of the class) and Avicenna Life Sci Master Fund LP directly holds 698,599 shares (about 0.8%). Combined, Mr. Raymond Debbane is disclosed as beneficial owner of 4,870,000 shares, representing 5.4% of the 90,811,368 shares outstanding used in the calculation. The filing states the positions were not acquired to change control of the issuer and lists addresses and organizational citizenship for each reporting person.
Rezolute, Inc. reported material financing and corporate items in its Form 10-K. The company completed an underwritten offering in April 2025 that generated aggregate gross proceeds of approximately $103.5 million and net proceeds of approximately $96.8 million. During fiscal 2025 the company also completed private placements that yielded net proceeds of $4.2 million and $6.0 million in prior periods, and issued pre-funded warrants and common stock in multiple transactions.
The filing discloses license and milestone obligations, including a $5.0 million milestone paid in May 2025 under the XOMA License Agreement upon dosing in a Phase 3 trial, a $25.0 million milestone due upon regulatory approval and up to $185.0 million of additional milestone payments tied to annual net sales. The company reports significant net operating loss (NOL) carryforwards totaling approximately $201.4 million with portions subject to expiration and IRC Section 382 limitations.
Rezolute, Inc. reported that it has released its financial results for the fourth quarter and fiscal year ended June 30, 2025. The company shared these results through a press release dated September 17, 2025, which is referenced as an exhibit to the current report. The disclosure indicates that detailed financial figures and commentary are contained in the accompanying press release rather than in this summary document.
Rezolute, Inc. reported that it has reached alignment with the U.S. Food and Drug Administration on the design of its ongoing Phase 3 trial of Ersodetug in tumor hyperinsulinism. This means the company and the regulator are now on the same page about how the late-stage study should be run, which is an important step for advancing the program.
The company also updated its corporate presentation to incorporate new information from the upLIFT study. These materials were shared through a press release and an investor presentation that are attached as exhibits to this current report.
Rezolute, Inc. (RZLT) Form 4 shows the company granted equity to its Chief Commercial Officer, Sunil Ratilal Karnawat. On 08/18/2025 Karnawat was awarded 25,000 restricted stock units that vest in four equal annual installments beginning 09/01/2026. The filing also reports an employee stock option grant to purchase 275,000 common shares at an exercise price of $6.55 per share, exercisable under a vesting schedule beginning one year after grant and completing monthly thereafter, with an expiration on 08/18/2035. Following the reported transactions, Karnawat directly beneficially owns 27,442 common shares and indirectly holds 8,000 shares in an IRA and 1,898 shares in an HSA. The Form 4 was signed by Karnawat on 08/27/2025.
Rezolute, Inc. (RZLT) Form 3 filed for Sunil Ratilal Karnawat reports initial beneficial ownership disclosures for an officer serving as Chief Commercial Officer. The filing shows 2,442 common shares held directly, plus 8,000 common shares held indirectly in an IRA and 1,898 common shares held indirectly in a Health Savings Account, for a total of 12,340 shares reported. The filing is signed and dated by the reporting person.
FAQ
What is the current stock price of Rezolute (RZLT)?
What is the market cap of Rezolute (RZLT)?
